Dec 31, 2025 • Benzinga
NEUTRAL
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
This article highlights three health care stocks with high dividend yields—Perrigo Company PLC (PRGO), Bristol-Myers Squibb Co (BMY), and CVS Health Corp (CVS)—drawing on analysis from highly accurate Wall Street analysts. It details recent analyst ratings, price target adjustments, and pertinent news for each company. The focus is on providing investors with insights into dividend-yielding opportunities in the health care sector during turbulent market conditions.
Dec 31, 2025 • MarketBeat
BULLISH
VIRGINIA RETIREMENT SYSTEMS ET Al Grows Stock Holdings in Bristol Myers Squibb Company $BMY
VIRGINIA RETIREMENT SYSTEMS ET Al significantly increased its stake in Bristol Myers Squibb Company ($BMY) by 43.7% in the third quarter of 2025, now holding 2,234,496 shares valued at $100.78 million. This makes BMY its 29th largest position, comprising approximately 0.7% of its holdings. Other institutional investors also adjusted their positions, and analysts currently rate BMY with a "Hold" consensus and an average price target of $54.62.
Dec 31, 2025 • MarketBeat
NEUTRAL
3Chopt Investment Partners LLC Sells 36,326 Shares of Bristol Myers Squibb Company $BMY
3Chopt Investment Partners LLC significantly reduced its stake in Bristol Myers Squibb Company by selling 36,326 shares, cutting their position by 57.9% in Q3. Despite the sell-off, other institutional investors increased their holdings in the biopharmaceutical company. Analysts currently have an average "Hold" rating on BMY with an average price target of $54.62, and the company recently raised its quarterly dividend to $0.63, offering a 4.6% yield.
Dec 31, 2025 • NAI500
NEUTRAL
Bristol-Myers Squibb Bets on the Future, Which Pipelines Will Become the New Pillars of Growth?
Goldman Sachs recently raised its target price for Bristol-Myers Squibb (BMY), noting a balance between risk and reward, alongside a strong dividend yield. The company is actively addressing patent expiry challenges for key products like Revlimid, Eliquis, and Opdivo through strategic acquisitions and R&D, aiming to diversify its pipeline and mitigate future revenue pressure. Despite anticipated challenges, Bristol-Myers Squibb is transforming its portfolio with innovative formulations, such as Opdivo Qvantig, to maintain the value of its core products and sustain growth.
Dec 31, 2025 • ts2.tech
NEUTRAL
Bristol-Myers Squibb stock edges higher as Wall Street drifts into year-end — what’s next for BMY
Bristol-Myers Squibb shares closed slightly higher on Tuesday amidst thin, year-end trading on Wall Street. Investors are looking ahead to the company's early-January dividend record date and its upcoming quarterly earnings report scheduled for February 5, 2026. The stock's performance reflects a modest gain as the broader market saw slight declines, with analysts noting the convergence of growth rates between technology and other sectors in the coming year.
Dec 30, 2025 • Finviz
SOMEWHAT-BULLISH
FDA Fast-Tracks Two Merck (MRK) Drugs With Blockbuster Potential
The FDA has fast-tracked two experimental Merck drugs, enlicitide decanoate for cholesterol and sacituzumab tirumotecan for cancer, through its Commissioner’s National Priority Voucher program. This initiative accelerates FDA decisions for drugs of major public health importance, potentially reducing review times from 10-12 months to one to two months. The move aims to strengthen Merck's pipeline as its top-selling cancer drug Keytruda faces impending biosimilar competition.